NCT04260932 - CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

May 10, 2021

Study Completion Date

September 10, 2021

Conditions

B-cell Lymphoma

Interventions

BIOLOGICAL

CD19/CD20 Dual-CAR-T cells

CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.

Trial Locations (1)

065200

Hebei Yanda Ludaopei Hospital, Sanhe

All Listed Sponsors

collaborator

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY

lead

Hebei Yanda Ludaopei Hospital

OTHER